922 related articles for article (PubMed ID: 34617959)
1. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
2. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Sharifova G; Cohen M; Lund JM; Mignatti A; Gianos E; Tafur A; Lewis PA; Cohoon K; Kittelson JM; Lesser ML; Sison CP; Rahman H; Ochani K; Hiatt WR; Dale RA; Anderson VE; Bonaca M; Halperin JL; Weitz JI; Spyropoulos AC
Thromb Haemost; 2021 Dec; 121(12):1684-1695. PubMed ID: 33823560
[TBL] [Abstract][Full Text] [Related]
3. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
4. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19.
Mennuni MG; Renda G; Grisafi L; Rognoni A; Colombo C; Lio V; Foglietta M; Petrilli I; Pirisi M; Spinoni E; Azzolina D; Hayden E; Aimaretti G; Avanzi GC; Bellan M; Cantaluppi V; Capponi A; Castello LM; D'Ardes D; Corte FD; Gallina S; Krengli M; Malerba M; Pierdomenico SD; Savoia P; Zeppegno P; Sainaghi PP; Cipollone F; Patti G;
J Thromb Thrombolysis; 2021 Oct; 52(3):782-790. PubMed ID: 33649979
[TBL] [Abstract][Full Text] [Related]
7. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD004318. PubMed ID: 30916777
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.
Canoglu K; Saylan B
Ann Saudi Med; 2020; 40(6):462-468. PubMed ID: 33307734
[TBL] [Abstract][Full Text] [Related]
9. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
Laporte S; Liotier J; Bertoletti L; Kleber FX; Pineo GF; Chapelle C; Moulin N; Mismetti P
J Thromb Haemost; 2011 Mar; 9(3):464-72. PubMed ID: 21232002
[TBL] [Abstract][Full Text] [Related]
10. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
[TBL] [Abstract][Full Text] [Related]
12. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial.
Rauch-Kröhnert U; Puccini M; Placzek M; Beyer-Westendorf J; Jakobs K; Friebel J; Hein S; Seidel M; Pieske B; Massberg S; Witzenrath M; Zeiher A; Friede T; Anker SD; Landmesser U
Clin Res Cardiol; 2023 Nov; 112(11):1620-1638. PubMed ID: 37407731
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
14. Thrombelastography-Based Dosing of Enoxaparin for Thromboprophylaxis in Trauma and Surgical Patients: A Randomized Clinical Trial.
Connelly CR; Van PY; Hart KD; Louis SG; Fair KA; Erickson AS; Rick EA; Simeon EC; Bulger EM; Arbabi S; Holcomb JB; Moore LJ; Schreiber MA
JAMA Surg; 2016 Oct; 151(10):e162069. PubMed ID: 27487253
[TBL] [Abstract][Full Text] [Related]
15. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD004318. PubMed ID: 30481366
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.
Sholzberg M; Tang GH; Rahhal H; AlHamzah M; Kreuziger LB; Áinle FN; Alomran F; Alayed K; Alsheef M; AlSumait F; Pompilio CE; Sperlich C; Tangri S; Tang T; Jaksa P; Suryanarayan D; Almarshoodi M; Castellucci LA; James PD; Lillicrap D; Carrier M; Beckett A; Colovos C; Jayakar J; Arsenault MP; Wu C; Doyon K; Andreou ER; Dounaevskaia V; Tseng EK; Lim G; Fralick M; Middeldorp S; Lee AYY; Zuo F; da Costa BR; Thorpe KE; Negri EM; Cushman M; Jüni P;
BMJ; 2021 Oct; 375():n2400. PubMed ID: 34649864
[TBL] [Abstract][Full Text] [Related]
17. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Lins PRG; de Albuquerque CCC; Assis CF; Rodrigues BCD; E Siqueira Campos BP; de Oliveira Valle E; Cabrera CPS; de Oliveira Gois J; Segura GC; Strufaldi FL; Mainardes LC; Ribeiro RG; Via Reque Cortes DDP; Lutf LG; de Oliveira MFA; Sales GTM; Smolentzov I; Reichert BV; Andrade L; Seabra VF; Rodrigues CE
Trials; 2020 Nov; 21(1):920. PubMed ID: 33176886
[TBL] [Abstract][Full Text] [Related]
18. In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
Bikdeli B; Garcia DA
Ann Intern Med; 2022 Feb; 175(2):JC17. PubMed ID: 35099994
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
[TBL] [Abstract][Full Text] [Related]
20. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
